Bart Filius
Known title: DirectorCIK: 0002115417
Bart Filius's purchase track record
Bart Filius has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/17/2026 | PRQR | $258K | -22.9% | pending | — |
| 6/26/2026 | PRQR | $231K | +7.8% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PRQR | ▲ Buy | Open Market | 150,000 | $258K | 7/17/2026 | View on chart |
| PRQR | ▲ Buy | Open Market | 150,000 | $231K | 6/26/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
ProQR Appoints New Chief Data and AI Officer and Board Advisor
ProQR Therapeutics has named Chris Hart as its new Chief Data and AI Officer and added Thomas Wolf to the board as a Strategic AI Advisor. These appointments signal a strategic focus on integrating artificial intelligence into the company's operations. The stock is currently trading near its 52-week low, with the recent leadership changes occurring while the share price remains well below the average analyst target.
ProQR Appoints New Chief Data and AI Officer and Board Advisor. ProQR Therapeutics has named Chris Hart as its new Chief Data and AI Officer and added Thomas Wolf to the board as a Strategic AI Advisor. These appointments signal a strategic focus on integrating artificial intelligence into the company's operations. The stock is currently trading near its 52-week low, with the recent leadership changes occurring while the share price remains well below the average analyst target.